The US vape company Glas stated that the newly disclosed internal records by the FDA show that the agency’s scientific review personnel had previously supported the market authorization of several flavored G2 products, but these products were subsequently halted by higher-ups. According to the documents obtained by the company through the Freedom of Information Act. The FDA’s Scientific Office initially recommended that all 8 products be approved in December 2025, and later supported the approval of 6 of them in February 2026, but the FDA ultimately only approved the G2 device and one tobacco-flavored cartridge for Glas in March.
Key Highlights of the Glas-FDA Dispute
- Glas submitted the G2 system PMTA application on July 21, 2021, covering an age verification device and 8 cartridge products.
- The FDA’s Scientific Office initially recommended that all 8 products be approved in December 2025, and later supported the approval of 6 of them in February 2026.
- In March 2026, the FDA only approved Glas’ G2 device and the Blonde Tobacco cartridge, and the 4 flavored cartridges were required to be temporarily denied market authorization.
- Glas claimed that its products focus on functions such as age and identity verification, anti-counterfeiting cartridge identification, and remote deactivation, and stated that the FDA had included this product in the “high-value products” fast-track review channel.
- Glas believes that the long-term unresolved status of the products is not only inconsistent with internal scientific conclusions but also raises questions at the administrative procedure law level.
Glas Accuses FDA of Contradicting Its Own Scientific Reviews
April 23, 2026. According to Nicotine Insider, the American vape brand Glas has accused the US Food and Drug Administration (FDA) of delaying its own scientific conclusions. The company stated that the newly disclosed internal records show that FDA reviewers had previously supported the authorization of several of its flavored products, but these products were subsequently halted by the agency’s top officials.
Background: Glas’ G2 System PMTA Application (2021)
The report indicates that the controversy centered on the G2 system marketing application (PMTA) submitted by Glas Inc. on July 21, 2021. This application covers a device with an age verification function and eight types of vape cartridges. The company emails and FDA memos obtained by Glas through the Freedom of Information Act show that the Scientific Office of the FDA’s Tobacco Products Center initially recommended on December 18, 2025, that market authorization be issued for all 8 SKUs.
FDA Scientific Office Supported Approval of 6 Glas Products
According to the report, on February 17, 2026, Matthew Farrelly. The director of the FDA’s Scientific Office, signed an opinion supporting the authorization of six products. Including devices, four flavored cartridges (two of which are menthol-flavored) and one tobacco-flavored cartridge. At the same time, he suggested that the other two tobacco-flavored cartridges, namely Blue Tobacco and Signature Tobacco, should continue to be reviewed due to issues related to the lifetime cumulative excess cancer risk value. The report states that Farrelly also explicitly stated that he did not want these two products to delay the authorization process for the rest of the products.
FDA Top Management Halts Authorization for 4 Flavored Cartridges
However, this review path did not continue. The report quotes another memorandum dated March 11, 2026, which states that Bret Koplow, the acting director of the Tobacco Products Center, wrote that Chief Deputy Commissioner Sara Brenner had instructed the agency on February 19 to “suspend the issuance of market authorization orders for four flavored cartridges. These four products are named Gold, Sapphire, Fresh Menthol, and Classic Menthol. Ultimately, on March 12th, the FDA only issued market authorization orders for the Glas G2 device and the Blonde Tobacco e-liquid cartridge.
Glas Condemns FDA’s Decision as Contrary to Its Review Process
On April 7th, Glas wrote to FDA Commissioner Marty Makary, Koplow and the agency’s legal advisor, stating that the Brenner memorandum “failed to adequately consider the science and evidence contained in the case files”. The company stated that this outcome “cannot be reconciled with the FDA’s own review process and the detailed analysis and recommendations of the agency’s scientific team.” Lawyer Stacy Ehrlich from Glas also stated that it seemed that “for unknown reasons, the political leadership of the FDA overturned the professional scientific conclusions of its tobacco scientists.”
Glas Highlights Product Features Addressing FDA Teen Exposure Concerns
The report states that for many years. Glas has positioned the G2 system as a response to the FDA’s concerns about the exposure of teenagers to electronic nicotine delivery systems (ENDS) and counterfeit products.
In a letter addressed to US Secretary of Health and Human Services Robert F. Kennedy Jr. and FDA officials. The company stated that this system features age and identity verification before first use, continuous user authentication, identification of counterfeit cartridges, prevention of unauthorized re-use of cartridges, and the ability to remotely deactivate the device. Glas also stated that the FDA had included their products in the “highly valuable products” fast-track review channel due to these contact restrictions.
Glas Presents Research Supporting Flavored Products for Adult Smoking Cessation
In his letter dated April 7th. Glas also stated that his application complies with the draft framework for the guidance on the risks of flavored ENDS for teenagers, which was released by the FDA in March 2026.
The company stated that the FDA had requested it to prove that these products could help adult smokers switch to or reduce cigarette consumption. Therefore, a 3-month, randomized conversion study involving 400 severely addicted adult smokers was included in its PMTA. According to Glas, after 3 months, among the participants using Glas products, 13% to 21% had completely quit smoking, 45% to 46% reduced their daily smoking amount by at least half, and if using the comprehensive benefit indicator, 79% to 92% showed a certain degree of decline.
Glas stated that the improvements were most noticeable in mint and other flavor products. The company also mentioned another practical usage study, stating that the daily cigarette consumption of smokers using Gold cartridges decreased by 73%, while that of smokers using Sapphire cartridges decreased by nearly 25%. Another perception study shows that smokers who are determined to quit smoking within 12 months are interested in the product, while teenagers, former smokers, and non-smokers have lower interest.
Glas: Minors Could Not Activate Devices in Age Verification Tests
Regarding the issue of teenagers’ exposure to problems, Glas stated that the evidence is stronger. The company stated that it conducted a series of functional and age verification tests, and no underage participants were able to activate the device. In his letter dated April 7th. Glas also cited statements from the FDA’s technical review, including “Age verification technology combined with marketing restrictions… is expected to be sufficient to mitigate the risks for teenagers”, and “100% of teenagers and young adults who did not reach the minimum sales age failed to pass the age verification”.
FDA’s Brenner Memo: Calls for More Time to Assess Flavored Products
However, Brenner’s memo took a different stance. According to Glas’ account, Brenner wrote that the FDA “has very little experience in assessing device contact limits in the context of ENDS”, so it needs “more time to consider” these four non-tobacco products, and instructed the Tobacco Products Center not to issue market authorization orders for them.
Internal FDA Disputes Tied to Broader Government Vape Policy Conflicts
The report suggests that the internal divisions within this institution are now embroiled in a larger political conflict within the government over the policy regarding flavored vapes. The Wall Street Journal previously reported that the White House had been pushing for the expansion of flavored vape products available to adults, while Makary opposed the authorization of new flavors and thwarted this effort. White House spokesperson Kush Desai stated that the government and the FDA “are completely in agreement on expanding the availability of flavored vapes for adults only”. Kennedy, to the lawmakers, said: “We are making every effort to bring vapes to the market in the United States. People are using these vapes to quit smoking, and this is something we are glad to see.”
Glas: PMTA Process Plagued by Inconsistencies and Delays
The report points out that the notable feature of the Glas case lies in the high degree of disclosure of relevant documents. In a letter sent to Kennedy on March 23rd, the company stated that the FDA had contacted them on December 17th, 2025, to arrange a teleconference on December 19th. However, the meeting was cancelled just a few hours before it was to start. The next day, the FDA also listed several Glas products on its authorized products webpage, including Blonde Tobacco, Classic Menthol, Fresh Menthol, Glas G2 equipment, Gold and Sapphire. Glas stated that after the company inquired, Koplow responded: “The Glas product has not been authorized. The application is still under review, and the website is immediately correcting the issue.”
Glas Questions FDA’s Compliance with Administrative Procedure Law
The company believes that this series of events. The scientific review being approved, the proposed phone call being arranged, the listing being publicly announced on the website, and then the withdrawal. Indicates that the institution was already prepared to proceed, but was ultimately stopped by certain factors or certain individuals. The company stated that the product has been “subject to unresolved regulatory issues” for nearly five years. Glas’s current decision to delay is not only regarded as a poor decision, but also potentially constitutes an issue under the Administrative Procedure Act. In their letters dated March 23rd and April 7th, the company stated that the FDA had exceeded the legally mandated 180-day PMTA review period by several years and had overturned the opinions of the scientific team without providing any clear public explanation.
Conclusion: The Role of Scientific Review in Flavored Vape Authorizations
The report concludes that Glas claims that its application has been under review for nearly five years, resulting in the related products remaining in a “regulatory pending” state. The report suggests that regardless of whether the FDA ultimately approves, rejects, or indefinitely postpones these vapes, the existing internal records have made a core issue in the ENDS market even more pronounced: when flavored products enter the agency’s office, how significant is the role of scientific review by the institution?
Follow us to get more updates: @zumo.official





